Vital Therapies Inc Stock Nasdaq
Equities
US92847R1041
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 114M 156M |
---|---|---|---|---|---|
Net income 2024 * | -99M -135M | Net income 2025 * | -100M -137M | EV / Sales 2024 * | - |
Net cash position 2024 * | 33.12M 45.26M | Net Debt 2025 * | 55.55M 75.91M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.27
x | P/E ratio 2025 * |
-1.45
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.28% |
Latest transcript on Vital Therapies Inc
Managers | Title | Age | Since |
---|---|---|---|
Daniel Vitt
CEO | Chief Executive Officer | 55 | 16-12-31 |
Glenn Whaley
DFI | Director of Finance/CFO | 56 | 19-11-30 |
Hella Kohlhof
CTO | Chief Tech/Sci/R&D Officer | 51 | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Barclay Phillips
BRD | Director/Board Member | 61 | 19-11-18 |
Tamar Howson
BRD | Director/Board Member | 75 | 19-10-10 |
Jörg Neermann
BRD | Director/Board Member | 57 | 19-03-31 |
1st Jan change | Capi. | |
---|---|---|
+5.66% | 109B | |
+11.23% | 105B | |
-0.38% | 22.25B | |
-12.15% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.09% | 16.85B | |
+3.33% | 13.76B | |
+36.58% | 12.46B |